Tumour proportion score (TPS)
The PD-L1 score used in lung cancer: the percentage of tumour cells that stain positive.
Assessed with the 22C3 assay. TPS ≥50% ('high') supports pembrolizumab or cemiplimab monotherapy; 1-49% favours chemo-immunotherapy; <1% still benefits from chemo-IO or CTLA-4-containing regimens (POSEIDON). Distinct from CPS (used in breast, gastric, head and neck), which also counts immune cells.
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-048
Shares Combined positive score (CPS), PD-L1, No one can predict who responds to immunotherapy, Pembrolizumab.
- PersonTasuku Honjo
Shares PD-L1, No one can predict who responds to immunotherapy, Pembrolizumab, Non-small-cell lung cancer.
- Key paperKEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation
Shares PD-L1, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised, Pembrolizumab.
- TrialKEYNOTE-B96 / ENGOT-ov65
Shares Combined positive score (CPS), PD-L1, Pembrolizumab.
- IdeaOne digital PD-L1 scale that maps across all the competing assays
Shares PD-L1, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised, Pembrolizumab.
- Key paperIwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack
Shares PD-L1, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised, Pembrolizumab.
- IdeaStanding reflex biomarker panels per tumour type, run without an oncologist's order
Shares Combined positive score (CPS), Biomarkers are not validated or standardised, Non-small-cell lung cancer.
- IdeaRandomise a cheap antihistamine alongside immunotherapy
Shares No one can predict who responds to immunotherapy, Pembrolizumab, Non-small-cell lung cancer.